Award
NIH Reporter #3R01AI184416-02S1
Therapeutic drug monitoring for linezolid in the treatment of rifampin-resistant tuberculosis: a pragmatic randomized controlled trial
Recipient
Albert Einstein College of Medicine, Bronx, NY, United States
Award Amount
$229,905.00
Ceiling
$229,905.00
Awarded
December 29, 2025
Identifier
3R01AI184416-02S1
A NIH-funded study to assess if therapeutic drug monitoring of linezolid can reduce toxicity and improve treatment adherence in rifampin-resistant tuberculosis patients in South Africa.
Description
This pragmatic, randomized controlled trial will evaluate the efficacy of linezolid therapeutic drug monitoring (TDM) in patients with rifampin-resistant tuberculosis (RR-TB) in South Africa to prevent linezolid-associated toxicity and premature discontinuation of therapy.